Chapter 4730-4 | Opioid Addiction Treatment

Rule 4730-4-01 | Definitions.

• Effective: October 31, 2024
• Promulgated Under: 119.03

(A) "Office-based opioid treatment" or "OBOT" means pharmacotherapy, in a private office or public sector clinic that is not otherwise regulated by practitioners authorized to prescribe outpatient supplies of medications approved by the United States food and drug administration for the treatment of opioid use disorder. OBOT includes treatment with all controlled substance medications approved by the United States food and drug administration for such treatment. OBOT does not include treatment that occurs in the following settings:

(1) A state or local correctional facility, as defined in section 5163.45 of the Revised Code;

(2) A hospital, as defined in section 3727.01 of the Revised Code;

(3) A provider certified to provide residential and inpatient substance use disorder services, including withdrawal management, by the Ohio department of mental health and addiction services;

(4) An opioid treatment program certified by SAMHSA and accredited by an independent SAMHSA-approved accrediting body;

(5) A youth services facility, as defined in section 103.75 of the Revised Code; and

(6) An emergency medical services agency as authorized under Chapter 4729. of the Revised Code.

(B) "SAMHSA" means the United States substance abuse and mental health services administration.

(C) "Addiction specialist physician" means a physician who holds one of the following medical subspecialty certifications:

(1) Subspecialty board certification in addiction medicine by the American board of preventative medicine ("ABPM");

(2) Subspecialty board certification in addiction psychiatry by the American board of psychiatry and neurology ("ABPN");

(3) Subspecialty board certification in addiction medicine by the American osteopathic association ("AOA"); or

(4) Certification by the American board of addiction medicine ("ABAM")

(D) "Medications for Opioid Use Disorder or MOUD" refers to all medications approved by the United States food and drug administration for the treatment of opioid use disorder.

(E) "Substance use disorder" indicates a problematic pattern of substance use leading to clinically significant impairment or distress, as determined by application of the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-Text Revision" or "DSM-5-TR."

(F) "OARRS" means the "Ohio Automated Rx Reporting System" drug database established and maintained pursuant to section 4729.75 of the Revised Code.

(G) For purposes of the rules in this chapter:

(1) "Qualified behavioral healthcare provider" means the following healthcare providers practicing within the scope of the professional license:

(a) Addiction medicine specialist physician or board certified psychiatrist, licensed under Chapter 4731. of the Revised Code;

(b) Psychologist, as defined in division (A) of section 4732.01 of the Revised Code, licensed under Chapter 4732. of the Revised Code;

(c) Licensed independent chemical dependency counselor-clinical supervisor, licensed independent chemical dependency counselor, licensed chemical dependency counselor III, licensed chemical dependency counselor II, or licensed chemical dependency counselor assistant licensed under Chapter 4758. of the Revised Code;

(d) Professional clinical counselor, licensed professional counselor, licensed independent social worker, licensed social worker, or marriage and family therapist, licensed under Chapter 4757. of the Revised Code;

(e) Advanced practice registered nurse, licensed as a clinical nurse specialist under Chapter 4723. of the Revised Code, who holds certification as a psychiatric mental health clinical nurse specialist issued by the American nurses credentialing center;

(f) Advanced practice registered nurse, licensed as a nurse practitioner under Chapter 4723. of the Revised Code, who holds certification as a psychiatric mental health nurse practitioner issued by the American nurses credentialing center; and

(g) Advanced practice registered nurse, licensed under Chapter 4723. of the Revised Code, who holds subspecialty certification as a certified addiction registered nurse-advanced practice issued by the addictions nursing certification board.

(2) Nothing in this paragraph shall be construed to prohibit a physician assistant licensed under Chapter 4730. of the Revised Code who practices under a supervision agreement with a board certified addiction psychiatrist, board certified addiction medicine specialist, or psychiatrist who is licensed as a physician under Chapter 4731. of the Revised Code, from providing services within the normal course of practice and expertise of the supervising physician, including addiction services, other mental health services, and physician delegated prescriptive services in compliance with Ohio and federal laws and rules.

(H) "Community addiction services provider" has the same meaning as in section 5119.01 of the Revised Code.

(I) "Community mental health services provider" has the same meaning as in section 5119.01 of the Revised Code.

(J) "Induction phase" means the phase of MOUD during which the patient is started on an FDA-approved medication for substance use disorder treatment.

(K) "Stabilization phase" means the period of time following the induction phase, when medication doses are adjusted to target a reduction in substance use disorder symptoms.

(L) "Maintenance phase" means the ongoing period of time when the patient's medication dose reaches a therapeutic level, allowing the patient to focus on other recovery activities.

(M) "Withdrawal management" is a set of medical interventions aimed at managing the acute physical symptoms of intoxication and withdrawal. Withdrawal management occurs when the patient has a substance use disorder and either evidence of the characteristic withdrawal syndrome produced by withdrawal from that substance, or evidence that supports the expectation that such a syndrome would develop without the provision of medical withdrawal management services. Withdrawal management alone does not constitute completed substance use disorder treatment or rehabilitation.

(N) "Ambulatory withdrawal management" means withdrawal management delivered in a medical office, public sector clinic, or urgent care facility by trained practitioners authorized to prescribe outpatient supplies of drugs approved by the United States food and drug administration for the treatment of substance use disorder. Ambulatory withdrawal management is the provision of medically supervised evaluation, treatment, and referral services without extended onsite monitoring. For purpose of rule 4730-4-02 of the Administrative Code, ambulatory withdrawal management does not include withdrawal management that occurs in the following settings:

(1) A state or local correctional facility, as defined in section 5163.45 of the Revised Code;

(2) In-patient treatment in a hospital, as defined in section 3727.01 of the Revised Code;

(3) A provider certified to provide residential and inpatient substance use disorder services, including withdrawal management, by the Ohio department of mental health and addition services;

(4) An opioid treatment program certified by SAMHSA and accredited by an independent SAMHSA-approved accrediting body;

(5) A youth services facility, as defined in section 103.75 of the Revised Code; and

(6) An emergency medical services agency as authorized under Chapter 4729. of the Revised Code.

Last updated October 31, 2024 at 8:45 AM

Supplemental Information

Authorized By: 4730.07, 4730.55
Amplifies: 4730.55, 4730.56
Five Year Review Date: 10/31/2029
Prior Effective Dates: 4/30/2019

Rule 4730-4-02 | Standards and procedures for withdrawal management for substance use disorder.

• Effective: October 31, 2024
• Promulgated Under: 119.03

(A) In order to provide ambulatory withdrawal management, as that term is defined in rule 4730-4-01 of the Administrative Code, a physician assistant shall comply with the following requirements:

(1) The physician assistant shall hold a valid prescriber number;

(2) The physician assistant shall provide withdrawal management under the supervision of a physician who provides withdrawal management as part of the physician's normal course of practice and with whom the physician assistant has a supervision agreement;

(3) The physician assistant shall comply with all state and federal laws and rules applicable to prescribing; and

(4) The physician assistant who practices in a healthcare facility shall comply with all policies of the healthcare facility concerning the provision of withdrawal management.

(B) Prior to providing ambulatory withdrawal management for any substance use disorder the physician assistant shall inform the patient that ambulatory withdrawal management alone is not complete treatment for a substance use disorder. If the patient prefers continuing treatment for a substance use disorder, the physician assistant shall comply with the requirements of section 3719.064 of the Revised Code.

(C) The physician assistant shall provide accurate, objective and complete documentation of all patient encounters, including referrals, test results, and significant changes to the treatment plan.

(D) When providing withdrawal management for opioid use disorder a physician assistant may be authorized to use a medical device that is approved by the United States food and drug administration as an aid in the reduction of opioid withdrawal symptoms.

(E) Ambulatory withdrawal management for opioid use disorder.

(1) The physician assistant shall provide ambulatory withdrawal management only when the following conditions are met:

(a) The patient has adequate social, medical, and psychiatric stability to engage in and safely complete ambulatory withdrawal management; and

(b) There is little risk of medication diversion.

(2) The physician assistant shall provide ambulatory withdrawal management under a defined set of policies and procedures or medical protocols, with patient placement in outpatient or residential settings consistent with American society of addiction medicine's level of care criteria. Such services are designed to treat the patient's level of clinical severity, to achieve safe and comfortable withdrawal from a drug, and to effectively facilitate the patient's transition into treatment and recovery. In the event that ambulatory withdrawal management is unsafe or inappropriate for a patient, referral to a higher level of care, such as inpatient hospitalization shall be completed. The ASAM criteria can be obtained from the website of the American society of addiction medicine at https://www.asam.org/. A copy of the ASAM criteria may be reviewed at the medical board office, 30 East Broad street, third floor, Columbus, Ohio, during normal business hours.

(3) Prior to providing ambulatory withdrawal management, the physician assistant shall perform an assessment of the patient to gather sufficient information and data to justify the use of this treatment intervention. The assessment shall include a thorough medical history and physical examination sufficient to assure safety in commencing ambulatory withdrawal management and shall include a review of the patient's prescription history in OARRS. The assessment must focus on signs and symptoms associated with opioid use disorder and include assessment with a nationally recognized scale, such as one of the following:

(a) "Objective Opioid Withdrawal Scale" (OOWS);

(b) "Clinical Opioid Withdrawal Scale" (COWS); or

(c) "Subjective Opioid Withdrawal Scale" (SOWS).

(4) If any part of the assessment cannot be completed prior to the initiation of treatment, the physician assistant shall complete as soon as possible following initiation of treatment.

(5) The physician assistant shall inform the patient about the following before treatment for opioid withdrawal is initiated:

(a) The withdrawal management process and importance of subsequent treatment for substance use disorder, including information about all medications approved by the United States food and drug administration for use in MOUD treatment;

(b) The risk of relapse and lethal overdose following completion of withdrawal without entry into continuation of MOUD treatment;

(c) The safe storage and disposal of prescribed medications.

(6) The physician assistant shall not establish standardized regimens of medications for management of substance withdrawal symptomatology but shall formulate an individualized treatment plan based on the needs of the specific patient.

(7) For persons projected to be involved in withdrawal management for six months or less, the physician assistant shall offer the patient counseling as described in paragraph (D) of rule 4730-4-03 of the Administrative Code.

(8) The physician assistant shall require the patient to undergo urine and/or other toxicological screenings during withdrawal management in order to assess for use of licit and/or illicit drugs. The physician assistant shall consider revising the treatment plan or referring a patient who has a positive toxicological screening result to a higher level of care, and shall confer with the supervising physician prior to prescribing the buprenorphine/naloxone combination product to the patient.

(9) The physician assistant shall comply with the following requirements for the use of medication:

(a) The physician assistant may treat the patient's withdrawal symptoms with any of the following medications as determined to be most appropriate for the patient.

(i) A medication that is specifically FDA approved for the alleviation of withdrawal symptoms. Methadone may only be utilized with strict adherence to the stipulations of 21 C.F.R. 1306.07(b).

(ii) An alpha-2 adrenergic agent along with other non-narcotic medications as recommended in the American society of addiction medicine's "National Practice Guideline" (https://www.asam.org/), which is available from the medical board's website at https://med.ohio.gov;

(iii) A combination of buprenorphine and low dose naloxone (buprenorphine/naloxone combination product), unless contraindicated, in which case buprenorphine mono-product may be utilized.

(b) The physician assistant shall not use anesthetic agents to treat the patient's withdrawal symptoms.

(c) The physician assistant shall comply with the following:

(i) Treatment with a buprenorphine product must be in compliance with the United States food and drug administration approved "Risk Evaluation and Mitigation Strategy" for buprenorphine products, which can be found on the United States food and drug administration website at the following address: https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm.

(ii) The physician assistant shall determine on an individualized basis the appropriate dosage of medication to ensure stabilization during withdrawal management.

(a) The dosage level shall be that which is effective in suppressing withdrawal symptoms and is well tolerated by the patient.

(b) The dosage level shall be consistent with the currently accepted standards of care.

(iii) In withdrawal management programs of thirty days or less duration, the physician assistant shall not prescribe nor dispense more than one week of unsupervised or take-home medications for the patient.

(10) The physician assistant shall offer the patient a prescription for an overdose reversal drug, directly provide them with the overdose reversal drug, or direct the patient to an easily accessible source to obtain the overdose reversal drug, such as http://www.naloxone.ohio.gov, a local health department, or other agency or facility that provides overdose reversal drugs.

(a) The physician assistant shall ensure that the patient and, if possible, those residing with the patient receive instruction on the drug's use including, but not limited to, recognizing the signs and symptoms of overdose and calling 911 in an overdose situation.

(b) The physician assistant shall offer the patient a new prescription for an overdose reversal drug upon expiration or use.

(c) The physician assistant shall be exempt from this requirement if the patient refuses the prescription. If the patient refuses the prescription the physician assistant shall provide the patient with information on where to obtain the overdose reversal drug without a prescription.

(11) The physician assistant shall take steps to reduce the risk of medication diversion by doing one or more of the following: frequent office visits, pill counts, urine drug screening, and frequent checks of OARRS.

(F) The physician assistant who provides ambulatory withdrawal management for benzodiazepines or other sedatives shall comply with paragraphs (A), (B), and (C) of this rule and "TIP 45, A Treatment Improvement Protocol for Detoxification and Substance Abuse Treatment" by the substance abuse and mental health services administration available from the substance abuse and mental health services administration website at the following link: https://store.samhsa.gov/. (Search for "TIP 45") and available on the medical board's website at: https://med.ohio.gov.

(1) The physician assistant shall provide ambulatory withdrawal management for benzodiazepines with medication only when a patient has sufficient social, medical, and psychiatric stability when their use of benzodiazepines was primarily in therapeutic dose ranges and when they do not have polysubstance dependence. The patient should exhibit no more than mild to moderate withdrawal symptoms, have no comorbid medical condition or severe psychiatric disorder, and no history of withdrawal seizures or withdrawal delirium.

(2) Prior to providing ambulatory withdrawal management, the physician assistant shall perform an assessment of the patient that focuses on signs and symptoms associated with benzodiazepine or other sedative use disorder and include assessment with a nationally recognized scale, such as the "Clinical Institute Withdrawal Assessment for Benzodiazepines" ("CIWA-B").

(3) Prior to providing ambulatory withdrawal management, the physician assistant shall conduct and document a biomedical and psychosocial evaluation of the patient to gather sufficient information and data to justify the use of this treatment intervention.

(4) The physician assistant shall instruct the patient about the following before treatment for benzodiazepine withdrawal management is initiated:

(a) Not to drive or operate dangerous machinery during treatment;.

(b) The withdrawal management process and importance of subsequent treatment for substance use disorder, including information about all medications approved by the United States food and drug administration for use in substance use disorder treatment;

(c) The risk of relapse and lethal overdose following completion of withdrawal without entry into continuation of treatment for substance use disorder; and

(d) The safe storage and disposal of prescribed medications.

(5) During the ambulatory withdrawal management, the physician assistant shall regularly assess the patient so that medication dosage can be adjusted if needed.

(a) The physician assistant shall require the patient to undergo urine and/or other toxicological screenings during withdrawal management in order to assess for the use of licit and/or illicit drugs.

(b) The physician assistant shall consider revising the treatment plan or referring the patient who has a positive toxicology screening to a higher level of care.

(c) The physician assistant shall take steps to reduce the chances of diversion by doing one or more of the following: frequent office visits, pill counts, urine drug screening, and frequent checks of OARRS.

(G) The physician assistant who provides ambulatory withdrawal management for withdrawal from alcohol addiction shall comply with paragraphs (A), (B), and (C) of this rule and "Clinical Practice Guideline on Alcohol Withdrawal Management" by the American society of addiction medicine available from the American society of addiction medicine website at the following link: http://www.asam.org/quality-care/clinical-guidelines/alcohol-withdrawal- management-guideline.

(1) The physician assistant shall provide ambulatory withdrawal from alcohol only when:

(a) The patient has sufficient social, medical, and psychiatric stability to adhere to prescribed treatments and successfully complete withdrawal with minimal risk of complications;

(b) The patient is not at risk for serious withdrawal from substances other than alcohol; and

(c) The patient has no history of withdrawal seizures or withdrawal delirium.

(2) Prior to providing ambulatory withdrawal management, the physician assistant shall perform an assessment of the patient. The assessment must focus on signs and symptoms associated with alcohol use disorder and include assessment with a nationally recognized scale, such as the "Clinical Institute Withdrawal Assessment for Alcohol-revised" ("CIWA-AR").

(3) Prior to providing ambulatory withdrawal management, the physician assistant shall perform a biomedical and psychosocial evaluation to gather sufficient information and data to justify the use of this treatment intervention.

(4) During the ambulatory withdrawal management, the physician assistant shall regularly assess the patient so that the dosage can be adjusted if needed.

(a) The physician assistant shall require the patient to undergo toxicological screenings in order to assess for the presence of alcohol metabolites, licit or illicit drugs;

(b) The physician assistant shall consider revising the treatment plan or referring a patient who has a positive toxicological screening test to a higher level of care; and

(c) The physician assistant shall take steps to reduce the risk of diversion by doing one or more of the following: frequent office visits, pill counts, urine drug screening, and frequent checks of OARRS.

Last updated October 31, 2024 at 8:45 AM

Supplemental Information

Authorized By: 4730.07, 4730.55
Amplifies: 4730.55, 4730.56
Five Year Review Date: 10/31/2029
Prior Effective Dates: 10/31/2020

Rule 4730-4-03 | Office-based opioid treatment.

• Effective: October 31, 2024
• Promulgated Under: 119.03

(A) A physician assistant who provides office-based opioid treatment ("OBOT") shall comply with the following requirements:

(1) Before initiating OBOT, the physician assistant shall comply with section 3719.064 of the Revised Code.

(2) Comply with all federal and state laws and regulations governing the prescribing of the medication;

(3) Complete at least eight hours of "Category 1" continuing medical education relating to substance use disorder and addiction every two years. Courses completed in compliance with this requirement shall be accepted toward meeting the continuing medical education requirement for biennial renewal of the physician assistant's license;

(4) Only provide OBOT if the provision of OBOT is within the supervising physician's normal course of practice and expertise;

(5) The physician assistant who provides OBOT shall perform an assessment of the patient to gather sufficient information and data to justify the use of this treatment intervention. The assessment shall include a thorough medical history, examination, and laboratory testing. If any part of the assessment cannot be completed prior to the initiation of OBOT, the physician assistant shall complete as soon as possible following initiation of treatment; and

(6) The physician assistant shall provide accurate, objective, and complete documentation of all patient encounters, including referrals, test results, and significant changes to the treatment plan.

(B) The physician assistant who provides OBOT shall establish a treatment plan that includes the following:

(1) The physician assistant's rationale for selection of the specific drug to be used in the treatment based upon discussion of all MOUDs and non-medication options with the patient;

(2) Patient education;

(3) Random urine-drug screens;

(4) A signed treatment agreement that outlines the responsibilities of the patient and the physician assistant, and documents the patient's consent for treatment;

(5) Documentation regarding psychosocial intervention, pursuant to paragraph (D) of this rule; and

(6) The treatment plan shall be revised if the patient does not show improvement with the original plan.

(C) The physician assistant shall provide OBOT in accordance with an acceptable treatment protocol for assessment, induction, stabilization, maintenance, and tapering. Acceptable protocols are any of the following:

(1) TIP 63 "Medications for Opioid Use Disorder" (2021) available from the https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder- Full-Document/PEP21-02-01-002.

(2) "ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update" available from the website of the American society of addiction medicine at: https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline.

(D) The physician assistant shall do the following with respect to psychosocial treatment for patients receiving OBOT:

(1) Assess for psychosocial treatment needs in addition to medication;

(2) Offer psychosocial interventions or referrals for psychosocial interventions to all patients, but OBOT should not be declined or discontinued if the patient is unable or unwilling to engage in psychosocial interventions;

(3) Ensure that psychosocial interventions are person-centered and tailored to the patient's insight, motivation, and stage of recovery;

(4) Focus the psychosocial interventions on retaining the patient in treatment, stabilizing the patient and assisting with progress in the patient's treatment and recovery;

(5) If the psychosocial interventions are not available or if the patient declines to participate, the physician assistant shall continue to treat the patient with OBOT provided that the patient adheres to all other treatment requirements;

(6) Psychosocial treatment or intervention includes the following:

(a) Cognitive behavioral treatment;

(b) Community reinforcement approach;

(c) Contingency management and motivational incentives;

(d) Motivational interviewing;

(e) Behavioral couples counseling;

(f) Twelve-step facilitation; and

(g) Other therapies based on the patient's individual needs;

(7) When necessary, the physician assistant may make referrals for psychosocial treatment to qualified behavioral healthcare providers, community addiction services or community mental health services providers as defined in rule 4730-4-01 of the Administrative Code; and

(8) The physician assistant may also refer patients for treatment with non-licensed paraprofessionals such as case managers and peer support specialists if the physician assistant determines such intervention would benefit the patient.

(E) The physician assistant who provides OBOT shall offer the patient a prescription for an overdose reversal drug, directly provide the patient with the overdose reversal drug, or direct the patient to an easily accessible source to obtain overdose reversal drugs, such as http://www.naloxone.ohio.gov, a local health department, or other agency or facility that provides overdose reversal drugs.

(1) The physician assistant shall ensure that the patient and, if possible, those residing with the patient, receive instruction on the overdose reversal drug's use including, but not limited to, recognizing the signs and symptoms of opioid overdose and calling 911 in an overdose situation.

(2) The physician assistant shall offer the patient a new prescription for an overdose reversal drug upon expiration or use.

(3) The physician assistant shall be exempt from this requirement if the patient refuses the prescription. If the patient refuses the prescription the physician assistant shall provide the patient with information on where to obtain overdose reversal drugs without a prescription.

(F) In addition to paragraphs (A) to (E) of this rule, the physician assistant who provides OBOT using buprenorphine products shall comply with the following requirements:

(1) Treatment with a buprenorphine product must be in compliance with the United States food and drug administration approved "Risk Evaluation and Mitigation Strategy" for buprenorphine products, which can be found on the United States food and drug administration website at the following address: https://www,accessdata.fda.gov/scripts/cder/rems/index.cfm. With the exception of those conditions listed in paragraph (G)(2) of this rule, a physician assistant who treats opioid use disorder with a buprenorphine product shall only prescribe buprenorphine/naloxone combination products for use in OBOT.

(2) The physician assistant may prescribe buprenorphine without naloxone (buprenorphine mono-product) only in the following situations:

(a) When a patient is pregnant or breast-feeding;

(b) When converting a patient from buprenorphine mono-product to buprenorphine/naloxone combination product;

(c) In formulations other than tablet or film form for indications approved by the United States food and drug administration; or

(d) When the patient has a genuine allergy to or intolerance of a buprenorphine/naloxone combination product.

(3) Due to a higher risk of fatal overdose when buprenorphine is prescribed with other opioids, benzodiazepines, sedative hypnotics, carisoprodol, gabapentin, or tramadol, the physician assistant shall only co-prescribe these substances when it is medically necessary.

(a) The physician assistant shall verify the diagnosis for which the patient is receiving the other drug and coordinate care with the prescriber for the other drug, including whether acceptable alternative treatments are available and whether it is possible to lower the dose or discontinue the drug. If the physician assistant prescribing buprenorphine is the prescriber of the other drug, the physician assistant shall also consider these options and consider consultation for another healthcare provider. The physician assistant shall educate the patient about the serious risks of the combined use.

(b) The physician assistant shall document the rationale for discontinuing, lowering, or continuing the medication given potential risks and benefits.

(4) During the induction phase the physician assistant shall not prescribe a dosage that exceeds the recommendation in the United States food and drug administration approved labeling, except for medically indicated circumstances as documented in the medical record. The physician assistant shall see the patient at least once a week during this phase.

(5) During the maintenance phase, the physician assistant shall prescribe a dosage of buprenorphine that avoids intoxication or sedation, prevents withdrawal, and suppresses significant drug craving. For the first twelve months of treatment, the physician assistant shall prescribe no more than a one-month supply of the buprenorphine product unless utilizing a formulation with duration of action exceeding one month, such as injections or implants.

(6) The physician assistant shall reduce the risk of buprenorphine diversion by using the lowest effective dose, and by using one or more of the following: scheduling appropriate frequency of office visits, conducting random pill counts, and checking OARRS and utilizing drug testing, serum medication levels, and oral fluid testing to assess for patient adherence to prescribed buprenorphine treatment.

(7) When using any sublingual formulation of buprenorphine, the physician assistant shall not prescribe a dosage exceeding twenty-four milligrams of buprenorphine per day, unless the physician assistant obtains a consultation from a addiction specialist physician recommending the higher dose. Dosage shall not exceed thirty-two milligrams of buprenorphine per day.

(8) The physician assistant shall incorporate relapse prevention strategies into the counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4730-4-01 of the Administrative Code, who has the education and experience to provide substance use disorder counseling.

(9) The physician assistant may treat a patient using the administration of an extended-release, injectable, or implanted buprenorphine product.

(a) The physician assistant shall strictly comply with any required risk evaluation and mitigation strategy for the drug.

(b) The physician assistant shall prescribe an extended-release buprenorphine product strictly in accordance with the United States food and drug administration's approved labeling for the drug's use.

(c) The physician assistant shall document in the patient record the rationale for the use of the extended-release buprenorphine product.

(d) The physician assistant who orders or prescribes an extended release, injectable, or implanted buprenorphine product shall require it to be administered by an Ohio licensed health care provider acting in accordance within the scope of their professional license.

Last updated October 31, 2024 at 8:45 AM

Supplemental Information

Authorized By: 4730.07, 4730.55
Amplifies: 4730.20, 4730.55, 4730.56
Five Year Review Date: 10/31/2029
Prior Effective Dates: 4/30/2019

Rule 4730-4-04 | Medication-assisted treatment using naltrexone.

• Effective: October 31, 2024
• Promulgated Under: 119.03

(A) In addition to the requirements in paragraphs (A) to (E) of rule 4730-4-03 of the Administrative Code, the physician assistant using naltrexone to treat opioid use disorder shall comply with the following requirements:

(1) Before initiating naltrexone, the physician assistant shall take measures to ensure that the patient is opioid abstinent for an adequate period of time after completing opioid withdrawal to avoid precipitated withdrawal. The physician assistant shall alert the patient of the risk of potentially lethal opioid overdose if they stop naltrexone and use opioids.

(2) The physician assistant shall use oral naltrexone only for treatment of patients who are highly motivated.

(a) The dosage regime shall strictly comply with the United States food and drug administration approved labeling for naltrexone hydrochloride tablets.

(b) The patient shall be encouraged to have a support person administer and supervise the medication. Examples of a support person are a family member, close friend, or employer.

(c) The physician assistant shall require urine drug screens, serum medication levels, or oral fluid drug testing at least every three months for the first year of treatment and at least every six months thereafter.

(d) The physician assistant shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4730-4-01 of the Administrative Code, who has the education and experience to provide substance use disorder counseling.

(B) The physician assistant may treat a patient with extended-release naltrexone for opioid or alcohol dependence or for co-occurring opioid and alcohol use disorders.

(1) The physician assistant should consider treatment with extended-release naltrexone for patients who have difficulties with treatment adherence.

(2) The dosage shall strictly comply with the United States food and drug administration approved labeling for extended-release naltrexone.

(3) The physician assistant shall determine the effectiveness of treatment with extended-release naltrexone by utilizing drug testing, serum medication levels, and oral fluid testing throughout the course of treatment.

(4) The physician assistant shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4730-4-01 of the Administrative Code, who has the education and experience to provide substance use disorder counseling.

Last updated October 31, 2024 at 8:45 AM

Supplemental Information

Authorized By: 4730.07, 4730.55
Amplifies: 4730.55, 4730.56
Five Year Review Date: 10/31/2029
Prior Effective Dates: 4/30/2019